SuperDNA Sdn Bhd and DOC2US Ink MoU to Provide Genetic Testing and Blood Screening Services
SuperDNA Sdn. Bhd., a privately held Malaysian genetic testing company, and DOC2US, Malaysia’s leading digital health platform and largest e-prescriptions issuer, have signed a memorandum of understanding (MoU) to provide Malaysians with a better preventive health ecosystem through its bundled packages for genetic testing and blood screening.
The collaboration looks to address the growing occurrence of non-communicable diseases (NCD) amongst Malaysians with nearly two-thirds of adult Malaysians suffering from at least 1 type of NCD. Through holistic health screening solutions, both parties hope to boost personalised preventive healthcare and thereby address this growing concern.
Commenting on the collaboration, SuperDNA CEO, Dr. Stefanie Chow said, “This collaboration with DOC2US is a great milestone for SuperDNA. DOC2US is the first tele-healthcare provider we are partnering and we are thrilled to be working with Malaysia’s leading digital health and e-prescription platform.”
“This collaboration will benefit many Malaysians, improving access to both genetic testing and blood screening at one go. This will allow them to gain deeper insights and have a better understanding of their overall health conditions thus enabling them to make informed decisions to improve their health. Personalized medicine is the future of healthcare, and genetic testing is the tool that makes it possible,” she added.
This MoU signifies the first step towards a long and collaborative partnership between SuperDNA and DOC2US, who both share core beliefs of preventive health.
Elaborating on the importance of this partnership, Chief Executive Officer and Co-founder of DOC2US, Dr. Raymond Choy said, “Malaysian healthcare is on a nationwide path towards wellness and preventive healthcare. Through this partnership, both DOC2US and SuperDNA will front preventive healthcare initiatives and precision medicine to address the nation’s ageing population and an increasing number of Non – Communicable Diseases (NCDs). The data obtained from precision medicine coupled with clinical data will provide better-personalised insights to both healthcare professionals and patients. As a result, early detection and more accurate diagnosis will improve patient outcomes and diagnosis through the amalgamation of genetic testing and telemedicine.”
The agreement was duly endorsed with the signatures of Dr. Stefanie Chow Yiing Yng, Chief Executive Officer of SuperDNA and Dr. Raymond Choy, Chief Executive Officer and Co-founder of DOC2US, witnessed by Ms. Fionne Teoh Yong Hooi, General Manager of SuperDNA and Mr Eng Kwang Meng, Chief Strategy Officer of DOC2US.
Original Source: Health Matters
